NKGen Biotech Will Present New Biomarker Data On SNK01 (Autologous Non-genetically Modified Nk Cell Therapy) In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1

7/18/24 8:13:44 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NKGN alert in real time by email

NKGen will present data on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant given that α-synuclein has been shown to correlate with worse cognitive function in Alzheimer's disease.

Get the next $NKGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NKGN

Date	Price Target	Rating	Analyst

More analyst ratings

$NKGN
Press Releases

Fastest customizable press release news feed in the world

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel therapy was well-tolerated and resulted in beneficial effects on protein aggregate levels and neuroinflammatory biomarkers in the cerebrospinal fluid, with decreases in pTau181 and GFAP appearing to be dose dependent. A larger trial with a higher dosing/duration has been initiated in the U.S. and is on-going. SANTA ANA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development a
2/13/25 8:00:00 AM ET
$NKGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease
The Fast Track designation accelerates troculeucel's path to U.S. FDA submission for the treatment of patients with moderate Alzheimer's disease. NKGen will benefit from increased FDA interactions, enhanced visibility and potential eligibility for Accelerated Approval, Priority Review, and Rolling Review of the regulatory dossier, with a faster path to market for troculeucel. SANTA ANA, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that the
2/12/25 8:00:00 AM ET
$NKGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
Upon closing, the transaction would secure global IP rights for NKGen.NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already legal.NKGen proposal included up to $18 million in committed funding.Closing expected in 1Q 2025. SANTA ANA, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced it has been selected as the preferred stalking horse bidder for NKMax Co., Ltd. ("NKMax
12/2/24 4:05:00 PM ET
$NKGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

NKGen Biotech Will Present New Biomarker Data On SNK01 (Autologous Non-genetically Modified Nk Cell Therapy) In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1

Chat with this insight

Recent Analyst Ratings for
$NKGN

$NKGN
Press Releases

Fastest customizable press release news feed in the world

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

$NKGN
Leadership Updates

Live Leadership Updates

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

$NKGN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by NKGen Biotech Inc.

SEC Form SC 13G/A filed by NKGen Biotech Inc. (Amendment)

$NKGN
Financials

Live finance-specific insights

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

$NKGN
SEC Filings

SEC Form DEF 14A filed by NKGen Biotech Inc.

SEC Form PRE 14A filed by NKGen Biotech Inc.

NKGen Biotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NKGN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

Large owner Graf Acquisition Partners Iv Llc disposed of 290,603 shares (SEC Form 4)

SEC Form 4 filed by Director Scott Kathleen D.

NKGen Biotech Will Present New Biomarker Data On SNK01 (Autologous Non-genetically Modified Nk Cell Therapy) In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1

Chat with this insight

Recent Analyst Ratings for $NKGN

$NKGN Press Releases

Fastest customizable press release news feed in the world

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

$NKGN Leadership Updates

Live Leadership Updates

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

$NKGN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by NKGen Biotech Inc.

SEC Form SC 13G/A filed by NKGen Biotech Inc. (Amendment)

$NKGN Financials

Live finance-specific insights

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

$NKGN SEC Filings

SEC Form DEF 14A filed by NKGen Biotech Inc.

SEC Form PRE 14A filed by NKGen Biotech Inc.

NKGen Biotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NKGN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

Large owner Graf Acquisition Partners Iv Llc disposed of 290,603 shares (SEC Form 4)

SEC Form 4 filed by Director Scott Kathleen D.

Recent Analyst Ratings for
$NKGN

$NKGN
Press Releases

$NKGN
Leadership Updates

$NKGN
Large Ownership Changes

$NKGN
Financials

$NKGN
SEC Filings

$NKGN
Insider Trading